State of Michigan Retirement System Has $203.42 Million Stock Position in Eli Lilly and Company $LLY

State of Michigan Retirement System grew its position in Eli Lilly and Company (NYSE:LLY) by 0.4% in the third quarter, Holdings Channel.com reports. The fund owned 266,604 shares of the company’s stock after buying an additional 1,100 shares during the period. Eli Lilly and Company makes up 1.0% of State of Michigan Retirement System’s investment portfolio, making the stock its 16th largest holding. State of Michigan Retirement System’s holdings in Eli Lilly and Company were worth $203,419,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Dash Acquisitions Inc. lifted its holdings in shares of Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after acquiring an additional 13 shares during the period. Nvest Financial LLC raised its position in Eli Lilly and Company by 0.6% in the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock worth $1,773,000 after purchasing an additional 13 shares in the last quarter. MPS Loria Financial Planners LLC lifted its stake in Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after purchasing an additional 13 shares during the period. Key Client Fiduciary Advisors LLC boosted its holdings in Eli Lilly and Company by 1.2% during the third quarter. Key Client Fiduciary Advisors LLC now owns 1,136 shares of the company’s stock valued at $867,000 after purchasing an additional 13 shares in the last quarter. Finally, Darwin Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 3.6% in the 3rd quarter. Darwin Wealth Management LLC now owns 373 shares of the company’s stock valued at $285,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and stunning 2026 guidance — Lilly reported strong Q4 revenue and EPS and issued 2026 guidance well above Street expectations, which sparked the initial rally as investors priced in sustained GLP‑1 growth and margin leverage. Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut
• Positive Sentiment: Analysts raising price targets — Multiple banks (JPMorgan, Morgan Stanley, Cantor Fitzgerald) lifted LLY price targets and kept overweight/positive views after the results, supporting upside expectations. Price Target Raised to $1,300.00 at JPMorgan Chase & Co. Price Target Raised to $1,313.00 at Morgan Stanley Price Target Raised to $1,205.00 at Cantor Fitzgerald
• Positive Sentiment: Manufacturing and capacity expansion — Lilly is expanding GLP‑1 capacity and building greenfield sites to meet volume demand, which investors view as a durable competitive advantage versus peers constrained by supply. Eli Lilly Expands GLP-1 Capacity While Building Beyond Obesity And Diabetes
• Neutral Sentiment: Obesity market size and longer‑term thesis — Coverage highlights a very large addressable market (approaching ~$100B for obesity drugs), reinforcing the long‑term growth story even as short‑term skirmishes play out. Eli Lilly vs Novo Nordisk: The 1 Figure Investors Shouldn’t Ignore
• Neutral Sentiment: Fund/score coverage — Research pieces (Zacks, institutional letters) reinforce Lilly’s growth ranking and investor interest, but are confirmatory rather than catalytic. Eli Lilly (LLY) is a Top-Ranked Growth Stock: Should You Buy?
• Negative Sentiment: Competitive pricing pressure from compounded copies — Hims & Hers launching low‑cost compounded semaglutide pills ($49 introductory) triggered a selloff as investors feared erosion of pricing/patient share for branded oral options. This remains the main short‑term risk to LLY’s oral launch economics. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Regulatory/legal noise — Separately, securities‑law firms have flagged investigations into certain transactions and board conduct; these are reputational/legal items to monitor but not yet material to the core GLP‑1 thesis. Investor Alert: Scott+Scott Investigates Directors and Officers

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday. Leerink Partners set a $1,234.00 price target on shares of Eli Lilly and Company in a report on Monday, January 5th. Finally, Wolfe Research boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,201.17.

Eli Lilly and Company Stock Up 3.6%

Shares of NYSE:LLY opened at $1,057.10 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market cap of $999.36 billion, a P/E ratio of 46.06, a P/E/G ratio of 0.74 and a beta of 0.39. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The company’s 50-day moving average price is $1,052.25 and its two-hundred day moving average price is $898.21.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the business earned $5.32 earnings per share. Eli Lilly and Company’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.